logo

RBOT

Vicarious Surgical·NYSE
--
--(--)
--
--(--)
0.36 / 10
Underperform

Fundamental assessment is weak, earning just 0.4 out of 10 points. Key concerns include negative net profit margin (-2976.84%) and net profit to revenue ratio (-2168.27%), both in the lowest performance group (1). Although Asset-MV and Cash-UP show some historical resilience, the overall balance sheet and earnings quality remain strained, indicating constrained financial health and limited margin of safety.

Fundamental(0.36)SentimentTechnical

Analysis Checks(3/10)

Revenue-MV
Value-0.26
Score0/3
Weight26.33%
1M Return-4.37%
Net profit attributable to parent company shareholders / Net profit (%)
Value100.00
Score2/3
Weight8.63%
1M Return-1.45%
Net cash flow from operating activities / Operating revenue (%)
Value-1515.96
Score0/3
Weight33.96%
1M Return-6.72%
Net income-Revenue
Value-0.15
Score1/3
Weight4.41%
1M Return-0.68%
Net profit margin (%)
Value-2976.84
Score0/3
Weight35.73%
1M Return-7.14%
Current assets turnover ratio
Value1.78
Score1/3
Weight6.37%
1M Return-0.98%
Cash-UP
Value-0.05
Score2/3
Weight-20.02%
1M Return2.84%
Asset-MV
Value-0.51
Score3/3
Weight-38.51%
1M Return4.39%
Net profit / Total operating revenue (%)
Value-2168.27
Score0/3
Weight35.30%
1M Return-7.04%
Cash-MV
Value-0.07
Score0/3
Weight7.80%
1M Return-1.26%
Is RBOT undervalued or overvalued?
  • RBOT scores 0.36/10 on fundamentals and holds a Premium valuation at present. Backed by its -130.51% ROE, 0.00% net margin, -0.26 P/E ratio, 1.00 P/B ratio, and 11.64% earnings growth, these metrics solidify its Underperform investment rating.